XXXX -based preoperative chemoradiotherapy with or without @entity901 for @entity5 : a 3-year follow-up study.

@entity901 @entity1 @entity137 @entity66 @entity416 @entity5 @entity294 @entity1349 @entity3 @entity1487
BACKGROUND: @entity1487 -based preoperative chemoradiotherapy has become the standard treatment for @entity5 . In order to improve the @entity1349 ( @entity1349 ) and @entity66 ( @entity66 ), we added @entity901 to the standard treatment, and compared the effectiveness of these two treatment patterns. METHODS: A total of 206 @entity1 enrolled in the prospective study had histologically confirmed @entity5 of clinical stage II/III during July 2007 to July 2010. They were randomized into the experimental group received @entity901 and @entity416 in combination with radiotherapy, and the control group received @entity416 in combination with radiotherapy. All @entity1 received surgery in 6-10 weeks after chemoradiotherapy and adjuvant chemotherapy with mFOLFOX6. The primary endpoints were @entity66 and @entity1349 , and the secondary endpoints included @entity137 , compliance, and histopathological response. RESULTS: The 3-year @entity1349 in the experimental group and the control group was 90.29% vs. 86.41% (P>0.05), and the 3-year @entity66 was 80.58% vs. 69.90% (P>0.05). The pathological complete remission (pCR) rates were 23.30% and 19.42%, respectively (P=0.497). The 3-year local recurrence rates were 4.85% vs. 5.83% (P=0.694), and the 3-year distant @entity3 rates were 16.50% and 28.16%, respectively (P=0.045). There were no significant differences in most grade 3-4 toxicities between two groups, however, grade 3-4 @entity294 occurred in 16.50% (17/103) of the experimental group, compared with 6.80% (7/103) of the control group (P=0.030). Also, the total grade 3-4 acute @entity137 showed a significant difference (10.68% vs. 21.36%, P=0.037). CONCLUSIONS: The experimental treatment did not lead significantly improved @entity1349 and @entity66 , and thus longer follow-up is warranted for our @entity1 cohort. Adding @entity901 to @entity416 -based preoperative chemoradiotherapy can significantly reduce @entity3 , but has only minimal impact on local recurrence. Although grade 3-4 @entity137 rate increased (primarily gastrointestinal @entity137 ), @entity1 can stand to be followed up with allopathic treatment.
